Medical Marijuana Inc. (OTC:MJNA).
The move comes on the heels of Kannnaway s entering into the U.S. cannabinol market with the introduction of two new CBN isolate products.
Each bottle of Kannaway s newly released product contains 200 milligrams of CBD and 500 milligrams of CBG coming from European organic hemp.
Products are certified via the company s Triple Lab Testing process, the San Diego company confirmed. As CBD continues to grow in acceptance around the world, the market for cannabinoids like CBG also expands, noted Kannaway CEO Blake Schroeder. Our company intends to continue to be at the forefront of expanding access to cannabinoids just as we have been with CBD.
Press release content from NewMediaWire. The AP news staff was not involved in its creation.
Medical Marijuana, Inc. Subsidiary Kannaway Enters CBG Market in Europe
Medical Marijuana, Inc.December 10, 2020 GMT
San Diego, CA - ( NewMediaWire ) - December 10, 2020 - Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that its subsidiary Kannaway(R) has officially entered the European cannabigerol (CBG) market with the release of its Kannaway(R) Premium CBG made with Organic Hemp Seed Oil.
“Since launching in Europe in 2018, Europe has become one of our best revenue-generating markets as consumers have responded very positively to Kannaway’s wide range of cannabidiol (CBD) products,” said Medical Marijuana, Inc. CEO Dr. Stuart Titus. “Similar to CBD, CBG is non-psychoactive, meani